Sarcoidosis Drug Market Report 2025

The sarcoidosis drug market size has grown strongly in recent years. It will grow from $7.43 billion in 2024 to $7.88 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to growing investment in orphan drug development, increasing research and development activities targeting granulomatous diseases, rising adoption of corticosteroids and immunosuppressants for symptom management, growing clinical pipeline of novel sarcoidosis therapeutics, and growing focus on personalized and targeted therapies.

The sarcoidosis drug market size is expected to see strong growth in the next few years. It will grow to $10.26 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing prevalence of sarcoidosis, rising awareness of rare and autoimmune diseases, growing number of diagnostic advancements enabling early detection, increasing healthcare expenditure, and rising patient access to specialty treatments and biologics. Major trends in forecast period includes advancements in immunotherapy technologies, integration of ai in drug discovery, technological advancements in diagnostic imaging, development of novel drug delivery systems, and integration of digital health tools.

The forecast of 6.8% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade barriers may hinder U.S. pulmonology clinics by increasing costs of tumor necrosis factor-alpha inhibitors and granuloma-targeting therapies sourced from Switzerland and Germany, potentially delaying treatment for inflammatory lung disease and raising rare condition management expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing number of clinical trials is expected to drive the growth of the sarcoidosis drug market. Clinical trials are research studies conducted on humans to assess the safety, effectiveness, and side effects of medical treatments or interventions. This rise in clinical trials is fueled by the growing demand for personalized and innovative treatments that require thorough safety and efficacy testing. Sarcoidosis drugs are used in these trials to evaluate their performance in improving patient outcomes and identifying more effective therapies. For example, in November 2023, the Association of the British Pharmaceutical Industry, a trade association based in London, reported a 15% increase in annual recruitment for industry clinical trials in the UK, with participant numbers rising from 36,722 in 2021-22 to 42,088 in 2022-23. As a result, the expanding number of clinical trials is contributing to the growth of the sarcoidosis drug market.

Major companies in the sarcoidosis drug market are focusing on the development of innovative therapies such as anti-TNFα monoclonal antibodies to address treatment-resistant cases and enhance disease management outcomes. These biologic drugs work by blocking tumor necrosis factor-alpha (TNFα), thereby reducing inflammation and tissue damage in conditions like sarcoidosis and other autoimmune diseases. In November 2023, Xentria Inc., a pharmaceutical company based in the US, received orphan drug designation from the European Medicines Agency (EMA) for XTMAB-16, a treatment for sarcoidosis. XTMAB-16 is a chimeric human-murine monoclonal antibody that targets TNFα, a critical inflammatory molecule involved in granuloma formation, which is characteristic of sarcoidosis. The drug is designed to interrupt the inflammatory process and potentially slow granuloma development, especially in pulmonary sarcoidosis, which impacts the lungs.

In June 2023, Xentria Inc. entered into a collaboration with Meitheal Pharmaceuticals Inc. to accelerate the development and commercialization of XTMAB-16. This partnership aims to deliver a targeted and effective treatment for pulmonary sarcoidosis, addressing a significant unmet medical need. Meitheal Pharmaceuticals Inc. is a US-based pharmaceutical manufacturer involved in the production of sarcoidosis drugs.

Major players in the sarcoidosis drug market are AbbVie Inc., Novartis AG., Viatris Inc., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Mallinckrodt plc, Kyorin Pharmaceutical Co. Ltd., Molecure S.A., aTyr Pharma Inc., Xentria Inc., Relief Therapeutics Holding AG, Foresee Pharmaceuticals Co. Ltd., OrphAI Therapeutics Inc., Bellus Health Inc., AI Therapeutics Inc., Araim Pharmaceuticals Inc., Kinevant Sciences GmbH, SarcoMed USA Inc.

North America was the largest region in the sarcoidosis drug market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sarcoidosis drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the sarcoidosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sarcoidosis drug market consists of sales of hydroxychloroquine, leflunomide, and cyclophosphamide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The sarcoidosis drug market research report is one of a series of new reports that provides sarcoidosis drug market statistics, including the sarcoidosis drug industry's global market size, regional shares, competitors with the sarcoidosis drug market share, detailed sarcoidosis drug market segments, market trends and opportunities, and any further data you may need to thrive in the sarcoidosis drug market. This sarcoidosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

A sarcoidosis drug refers to any pharmacological substance used to manage the abnormal immune activity and granuloma development associated with sarcoidosis - a systemic inflammatory disease that primarily affects the lungs and lymph nodes. These medications work to alleviate symptoms and prevent damage to organs.

The primary types of sarcoidosis drugs are targeted for conditions such as ocular sarcoidosis, neurosarcoidosis, cardiac sarcoidosis, musculoskeletal sarcoidosis, cutaneous sarcoidosis, renal sarcoidosis, hepatic sarcoidosis, and sarcoidosis of the spleen, bone marrow, and lungs. Ocular sarcoidosis refers specifically to inflammation in the eyes caused by the disease, marked by the formation of granulomas in ocular tissues. This can lead to symptoms like redness, pain, and potential vision loss. Treatment approaches include corticosteroids, immunosuppressants, antimalarial drugs, and tumor necrosis factor-alpha (TNF-alpha) inhibitors. These medications are used to treat organ involvement in the lungs, skin, heart, and nervous system, and they can be administered orally, intravenously, or topically. Key end users include hospitals, clinics, surgical centers, diagnostic centers, and other healthcare institutions.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.